Loading stock data…
Rhythm Pharmaceuticals, Inc. (RYTM)
$101.80-0.94 (-0.91%)
Market ClosedLast close Sep 8
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rhythm Pharmaceuticals, Inc. in the Healthcare sector is trading at $101.80 with a market capitalization of $8.0B. Wall Street consensus targets $140.19 (16 analysts), implying a +37.7% move over the next 12 months. The stock is currently 17% below its 52-week high of $122.20, remaining 2.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +37.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 24) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $71.25M↑ | $60.11M↑ | $57.25M↑ | $51.30M↑ | $48.50M |
| Gross Profit | $62.32M↑ | $52.95M↑ | $52.45M↑ | $45.80M↑ | $42.96M |
| Operating Income | -$48.55M↑ | -$52.36M↓ | -$47.06M↑ | -$52.65M↓ | -$45.30M |
| Net Income | -$49.30M↑ | -$55.64M↓ | -$47.51M↑ | -$52.90M↓ | -$46.63M |
Peer Comparison
JNJUNHPFE
Fundamentals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.95B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-94.50%
Volume
Today's trading volume
512,579
Recent News
An AI drug specialist zeroes in on rare forms of obesity
Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed medicine Imcivree.
Moderna upgraded, Allstate downgraded: Wall Street's top analyst calls
Moderna upgraded, Allstate downgraded: Wall Street's top analyst calls
Here Are Friday’s Top Wall Street Analyst Research Calls: Baozun, Commerce Bancshares, Element Solutions, Evolution Petroleum, Petrobras, Rythm Pharmaceuticals, Terawulf, UMB Financial, Workday, and More
NVIDIA's blockbuster earnings sent shockwaves through tech on Thursday, but Wall Street analysts were busy reshaping the landscape elsewhere, issuing a flurry of upgrades, downgrades, and fresh initiations across energy, crypto infrastructure, banking, and biotech.
Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run
Rhythm Pharmaceuticals has delivered very strong long-term share price gains, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. The stock is up about 7x over 5 years, which puts extra focus on whether recent gains already reflect much of the company story. Approval of IMCIVREE for acquired hypothalamic obesity in Japan may support expectations for future revenue growth, while execution risk around pricing, uptake...
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
Could this little-known biotech be a hidden gem?